Oncaspar New Zealand - English - Medsafe (Medicines Safety Authority)

oncaspar

servier laboratories nz ltd - pegaspargase 3750 u (4050u including overage) - powder for injection - 3750 u/5ml - active: pegaspargase 3750 u (4050u including overage) excipient: dibasic sodium phosphate hydrochloric acid monobasic sodium phosphate sodium chloride sodium hydroxide sucrose - oncaspar is indicated as a component of antineoplastic combination therapy in patients with acute lymphoblastic leukaemia (all).

ONCASPAR SOLUTION Canada - English - Health Canada

oncaspar solution

servier canada inc - pegaspargase - solution - 750unit - pegaspargase 750unit - antineoplastic agents

ONCASPAR POWDER FOR SOLUTION FOR INJECTIONINFUSION 750 UML Singapore - English - HSA (Health Sciences Authority)

oncaspar powder for solution for injectioninfusion 750 uml

servier (s) pte ltd - pegaspargase - injection, powder, lyophilized, for solution - pegaspargase 750 u/ml

ONCASPAR LIQUID Canada - English - Health Canada

oncaspar liquid

aventis pharma inc - pegaspargase - liquid - 750unit - pegaspargase 750unit - antineoplastic agents

Oncaspar European Union - English - EMA (European Medicines Agency)

oncaspar

les laboratoires servier - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

Oncaspar 750 U/mL Powder for Solution for Injection/ Infusion   (IV/IM) Philippines - English - FDA (Food And Drug Administration)

oncaspar 750 u/ml powder for solution for injection/ infusion (iv/im)

les laboratoires servier; importer: servier philippines, inc.; distributor: zuellig pharma corporation - pegaspargase - powder for solution for injection/ infusion (iv/im) - 750 u/ml